

Alice B Gottlieb

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3797640/alice-b-gottlieb-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

170
papers

8,866
citations

42
h-index

93
g-index

187
ext. papers

10,774
ext. citations

6
avg, IF

6.01
L-index

| # | Paper | IF | Citations |
|-----|--|-----|-----------|
| 170 | Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial.. <i>Dermatology and Therapy</i> , 2022 , 12, 495 | 4 | 6 |
| 169 | Clinical Disease Measures in Generalized Pustular Psoriasis.. <i>American Journal of Clinical Dermatology</i> , 2022 , 23, 39 | 7.1 | 1 |
| 168 | Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data.. <i>Acta Dermato-Venereologica</i> , 2022 , | 2.2 | 4 |
| 167 | Telemedicine and psoriatic arthritis: best practices and considerations for dermatologists and rheumatologists.. <i>Clinical Rheumatology</i> , 2022 , 1 | 3.9 | 1 |
| 166 | Secukinumab demonstrates high and sustained efficacy in nail psoriasis: Post hoc analysis from phase 3 trials in patients with psoriatic arthritis.. <i>British Journal of Dermatology</i> , 2022 , | 4 | |
| 165 | Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis.. <i>Dermatology and Therapy</i> , 2022 , 12, 911 | 4 | |
| 164 | Examination of Treatment Satisfaction Instruments in Psoriasis: 2017 Results from the Psoriasis Working Group of the International Dermatology Outcome Measures (IDEOM). <i>Dermatology</i> , 2021 , 237, 151-157 | 4.4 | 4 |
| 163 | Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021 , 13, 1759726X211057077 | 3.8 | 1 |
| 162 | Long-term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through 2 Years: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naïve Patients with Active Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2021 , | 9.5 | 4 |
| 161 | Secukinumab Efficacy in Psoriatic Arthritis: Machine Learning and Meta-analysis of Four Phase 3 Trials. <i>Journal of Clinical Rheumatology</i> , 2021 , 27, 239-247 | 1.1 | 9 |
| 160 | Clinical implications and predictive values of early PASI responses to tildrakizumab in patients with moderate-to-severe plaque psoriasis. <i>Journal of Dermatological Treatment</i> , 2021 , 1-6 | 2.8 | 0 |
| 159 | Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 1147-1157 | 2.4 | 10 |
| 158 | Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2021 , 48, 1815-1823 | 4.1 | 3 |
| 157 | Musculoskeletal Imaging for Dermatologists: Techniques in the Diagnosis and Management of Psoriatic Arthritis. <i>Dermatology and Therapy</i> , 2021 , 11, 1199-1216 | 4 | 2 |
| 156 | Signal Detection and Methodological Limitations in a Real-World Registry: Learnings from the Evaluation of Long-Term Safety Analyses in PSOLAR. <i>Drug Safety</i> , 2021 , 44, 699-709 | 5.1 | 0 |
| 155 | A clinical perspective on risk factors and signs of subclinical and early psoriatic arthritis among patients with psoriasis. <i>Journal of Dermatological Treatment</i> , 2021 , 1-9 | 2.8 | 1 |
| 154 | Efficacy of ruxolitinib cream in vitiligo by patient characteristics and affected body areas: Descriptive subgroup analyses from a phase 2, randomized, double-blind trial. <i>Journal of the American Academy of Dermatology</i> , 2021 , | 4.5 | 5 |

| | | | |
|-----|--|-----|----|
| 153 | Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM), a Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Data from the BELVIVID and BEIREADY Phase III Trials. <i>Dermatology and Therapy</i> , 2021 , 11, 1551-1569 | 4 | 1 |
| 152 | Axial psoriatic arthritis: An update for dermatologists. <i>Journal of the American Academy of Dermatology</i> , 2021 , 84, 92-101 | 4.5 | 13 |
| 151 | Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2). <i>Journal of the American Academy of Dermatology</i> , 2021 , 84, 398-407 | 4.5 | 3 |
| 150 | Efficacy and Safety of Guselkumab, an Interleukin-23p19-Specific Monoclonal Antibody, Through One Year in Biologic-Naive Patients With Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2021 , 73, 604-616 | 4.5 | 16 |
| 149 | Interactive, Proof of Concept Clinical Trial Design in Hidradenitis Suppurativa. <i>Journal of Investigative Dermatology</i> , 2021 , 141, 431-433 | 4.3 | 1 |
| 148 | Low gene expression of TNF, IL17A, IL23A, and IL12B in tumors: A safety surrogate to predict cancer survival associated with biologic therapies. <i>Journal of the American Academy of Dermatology</i> , 2021 , 85, 249-252 | 4.5 | 0 |
| 147 | Characteristics of Patients with Psoriasis Treated with Apremilast in the Corrona Psoriasis Registry. <i>Dermatology and Therapy</i> , 2021 , 11, 253-263 | 4 | 0 |
| 146 | Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM): A Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Reported Data from the BE RADIANT Phase 3b Trial. <i>Advances in Therapy</i> , 2021 , 38, 5253-5269 | 4.1 | 0 |
| 145 | Dupilumab in HIV-positive patients: A case series report of 4 patients. <i>JAAD Case Reports</i> , 2020 , 6, 1356-1359 | 4.5 | 2 |
| 144 | Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. <i>Lancet, The</i> , 2020 , 395, 1496-1505 | 4.0 | 83 |
| 143 | Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, 1367-1374 | 4.5 | 28 |
| 142 | Malignancy Rates in Brodalumab Clinical Studies for Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2020 , 21, 421-430 | 7.1 | 6 |
| 141 | Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2020 , 395, 1126-1136 | 4.0 | 90 |
| 140 | Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial. <i>Lancet, The</i> , 2020 , 396, 110-120 | 4.0 | 59 |
| 139 | Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. <i>Lancet, The</i> , 2020 , 395, 427-440 | 4.0 | 65 |
| 138 | Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: Results of an open-label trial. <i>Journal of the American Academy of Dermatology</i> , 2020 , 82, 1524-1526 | 4.5 | 23 |
| 137 | Measurement properties of instruments assessing psoriatic arthritis symptoms for psoriasis clinical trials: a systematic literature review. <i>Expert Review of Clinical Immunology</i> , 2020 , 16, 267-283 | 5.1 | 2 |
| 136 | Investigator and Patient Global Assessment Measures for Psoriasis Clinical Trials: A Systematic Review on Measurement Properties from the International Dermatology Outcome Measures (IDEOM) Initiative. <i>American Journal of Clinical Dermatology</i> , 2020 , 21, 323-338 | 7.1 | 0 |

| | | | |
|-----|--|-----|----|
| 135 | A Phase II Open-Label Study of Bermekimab in Patients with Hidradenitis Suppurativa Shows Resolution of Inflammatory Lesions and Pain. <i>Journal of Investigative Dermatology</i> , 2020 , 140, 1538-1545 | 4.3 | 27 |
| 134 | Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. <i>Journal of the American Academy of Dermatology</i> , 2020 , 82, 161-201 | 4.5 | 63 |
| 133 | Clinical efficacy and safety of secukinumab in patients with psoriasis and comorbidities: pooled analysis of 4 phase 3 clinical trials. <i>Journal of Dermatological Treatment</i> , 2020 , 1-9 | 2.8 | 4 |
| 132 | Report from the International Dermatology Outcome Measures Initiative. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2020 , 20, S80-S83 | 1.1 | 1 |
| 131 | Development and Content Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM) for Assessment of Plaque Psoriasis. <i>Dermatology and Therapy</i> , 2020 , 10, 1255-1272 | 4 | 4 |
| 130 | Psoriatic arthritis for dermatologists. <i>Journal of Dermatological Treatment</i> , 2020 , 31, 662-679 | 2.8 | 20 |
| 129 | Tildrakizumab efficacy and safety are not altered by metabolic syndrome status in patients with psoriasis: Post hoc analysis of 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2). <i>Journal of the American Academy of Dermatology</i> , 2020 , 82, 519-522 | 4.5 | 9 |
| 128 | Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II Trial. <i>Arthritis Care and Research</i> , 2020 , 72, 1579-1588 | 4.7 | 4 |
| 127 | Treatment of Medicare Patients with Moderate-to-Severe Psoriasis who Cannot Afford Biologics or Apremilast. <i>American Journal of Clinical Dermatology</i> , 2020 , 21, 109-117 | 7.1 | 3 |
| 126 | Indirect comparisons of ixekizumab versus three interleukin-23 p19 inhibitors in patients with moderate-to-severe plaque psoriasis - efficacy findings up to week 12. <i>Journal of Dermatological Treatment</i> , 2020 , 1-8 | 2.8 | 5 |
| 125 | 256 Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 4-year results from the Phase 3 FUTURE 2 study. <i>Rheumatology</i> , 2019 , 58, | 3.9 | 3 |
| 124 | Achieving Consensus on Patient-Reported Outcome Measures in Clinical Practice for Inflammatory Skin Disorders: On Behalf of International Dermatology Outcome Measures and the American Academy of Dermatology. <i>Journal of the American Academy of Dermatology</i> , 2019 , | 4.5 | 6 |
| 123 | Exploration of the Product of the 5-Point Investigator® Global Assessment and Body Surface Area (IGA IBSA) as a Practical Minimal Disease Activity Goal in Patients with Moderate-to-Severe Psoriasis. <i>Dermatology</i> , 2019 , 235, 348-354 | 4.4 | 4 |
| 122 | Probiotics for oral and vulvovaginal candidiasis: A review. <i>Dermatologic Therapy</i> , 2019 , 32, e12970 | 2.2 | 10 |
| 121 | The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1215-1219 | 2.4 | 21 |
| 120 | Discrete Papular Lichen Myxedematosus and Scleromyxedema with Hypothyroidism: A Report of Two Cases. <i>Case Reports in Dermatology</i> , 2019 , 11, 64-70 | 1.1 | 1 |
| 119 | Clinical considerations for the management of psoriasis in women. <i>International Journal of Womens Dermatology</i> , 2019 , 5, 141-150 | 2 | 24 |
| 118 | Association Between Enthesitis and Health-related Quality of Life in Psoriatic Arthritis in Biologic-naive Patients from 2 Phase III Ustekinumab Trials. <i>Journal of Rheumatology</i> , 2019 , 46, 1458-1461 | 4.1 | 10 |

| | | | |
|-----|---|-----|-----|
| 117 | A provider global assessment quality measure for clinical practice for inflammatory skin disorders. <i>Journal of the American Academy of Dermatology</i> , 2019 , 80, 823-828 | 4.5 | 3 |
| 116 | Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. <i>Journal of the American Academy of Dermatology</i> , 2019 , 80, 1029-1072 | 4.5 | 296 |
| 115 | Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. <i>Journal of the American Academy of Dermatology</i> , 2019 , 80, 1073-1113 | 4.5 | 145 |
| 114 | AB0738 DUAL NEUTRALISATION OF INTERLEUKIN (IL) 17A AND IL 17F WITH BIMEKIZUMAB IN MODERATE-TO-SEVERE PLAQUE PSORIASIS: 60-WEEK RESULTS FROM A RANDOMISED, DOUBLE-BLINDED, PHASE 2B EXTENSION STUDY 2019 , | | 1 |
| 113 | Serious infections in patients with self-reported psoriatic arthritis from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) treated with biologics. <i>BMC Rheumatology</i> , 2019 , 3, 52 | 2.9 | 14 |
| 112 | Safety of Ixekizumab in Patients With Psoriatic Arthritis: Results From a Pooled Analysis of Three Clinical Trials. <i>Arthritis Care and Research</i> , 2019 , 71, 367-378 | 4.7 | 36 |
| 111 | Clinical Goals and Barriers to Effective Psoriasis Care. <i>Dermatology and Therapy</i> , 2019 , 9, 5-18 | 4 | 44 |
| 110 | Improving health literacy and treatment understanding of hidradenitis suppurativa using group educational interventions. <i>Journal of Dermatological Treatment</i> , 2019 , 30, 708-713 | 2.8 | 3 |
| 109 | Comparison of Different Remission and Low Disease Definitions in Psoriatic Arthritis and Evaluation of Their Prognostic Value. <i>Journal of Rheumatology</i> , 2019 , 46, 160-165 | 4.1 | 12 |
| 108 | Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. <i>Journal of the American Academy of Dermatology</i> , 2019 , 80, 251-265.e19 | 4.5 | 186 |
| 107 | Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2). <i>Journal of the American Academy of Dermatology</i> , 2018 , 79, 302-314.e6 | 4.5 | 94 |
| 106 | Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. <i>Journal of the American Academy of Dermatology</i> , 2018 , 79, 277-286.e10 | 4.5 | 105 |
| 105 | The Development of the Genital Psoriasis Sexual Frequency Questionnaire (GenPs-SFQ) to Assess the Impact of Genital Psoriasis on Sexual Health. <i>Dermatology and Therapy</i> , 2018 , 8, 33-44 | 4 | 11 |
| 104 | The Development of a Patient-Reported Outcome Measure for Assessment of Genital Psoriasis Symptoms: The Genital Psoriasis Symptoms Scale (GPSS). <i>Dermatology and Therapy</i> , 2018 , 8, 45-56 | 4 | 14 |
| 103 | Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation. <i>Journal of the American Academy of Dermatology</i> , 2018 , 78, 383-394 | 4.5 | 41 |
| 102 | Effect of psoriatic arthritis on ixekizumab clinical outcomes in moderate-to-severe psoriasis patients: A post hoc analysis. <i>Journal of the American Academy of Dermatology</i> , 2018 , 79, 593-595 | 4.5 | 3 |
| 101 | Evaluation of sPGA/BSA as an Outcome Measure and Treatment Target for Clinical Practice. <i>Journal of Investigative Dermatology</i> , 2018 , 138, 1955-1961 | 4.3 | 15 |
| 100 | 4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis. <i>RMD Open</i> , 2018 , 4, e000582 | 5.9 | 25 |

| | | | |
|----|---|-----|-----|
| 99 | Importance of light in the treatment of vitiligo with JAK-inhibitors. <i>Journal of Dermatological Treatment</i> , 2018 , 29, 98-99 | 2.8 | 16 |
| 98 | Trial Characteristics as Contextual Factors When Evaluating Targeted Therapies in Patients With Psoriatic Disease: A Meta-Epidemiologic Study. <i>Arthritis Care and Research</i> , 2018 , 70, 1206-1217 | 4.7 | 4 |
| 97 | Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1). <i>Rheumatology</i> , 2018 , 57, 1777-1788 | 3.9 | 15 |
| 96 | Are Your Patients Satisfied A Systematic Review of Treatment Satisfaction Measures in Psoriasis. <i>Dermatology</i> , 2018 , 234, 157-165 | 4.4 | 7 |
| 95 | Identifying a Core Domain Set to Assess Psoriasis in Clinical Trials. <i>JAMA Dermatology</i> , 2018 , 154, 1137-1144 | 4.4 | 24 |
| 94 | Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2018 , 70, 345-355 | 9.5 | 51 |
| 93 | Demography, baseline disease characteristics, and treatment history of psoriasis patients with self-reported psoriatic arthritis enrolled in the PSOLAR registry. <i>BMC Rheumatology</i> , 2018 , 2, 29 | 2.9 | 8 |
| 92 | Apremilast in Combination With an Interleukin 17A Inhibitor in the Treatment of Recalcitrant Palmoplantar Psoriasis: A Chart Review. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2018 , 3, 122-125 | 1.1 | 2 |
| 91 | Interleukin-17 Inhibition in a Patient With Psoriasis and Concurrent Vitiligo. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2018 , 3, 126-130 | 1.1 | 1 |
| 90 | Bimekizumab for the treatment of psoriatic disease. <i>Expert Opinion on Biological Therapy</i> , 2018 , 18, 1193-1197 | 5.1 | 11 |
| 89 | Patient-Reported Outcome Measures for Pediatric Psoriasis: A Systematic Review and Critical Appraisal from International Dermatology Outcome Measures (IDEOM). <i>Dermatology</i> , 2018 , 234, 112-119 | 4.4 | 1 |
| 88 | Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study. <i>Lancet, The</i> , 2018 , 391, 2213-2224 | 4.0 | 113 |
| 87 | Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept. <i>Journal of the American Academy of Dermatology</i> , 2017 , 76, 655-661 | 4.5 | 20 |
| 86 | Protocol for the development of a core domain set for hidradenitis suppurativa trial outcomes. <i>BMJ Open</i> , 2017 , 7, e014733 | 3 | 24 |
| 85 | Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1550-1558 | 2.4 | 129 |
| 84 | Incidence and prevalence of psoriatic arthritis in Denmark: a nationwide register linkage study. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1591-1597 | 2.4 | 33 |
| 83 | Practical Assessment of Psoriasis Clinical Severity in both Clinical Trials and Clinical Practice Settings: A Report from the GRAPPA 2016 Annual Meeting. <i>Journal of Rheumatology</i> , 2017 , 44, 691-692 | 4.1 | 1 |
| 82 | Defining Outcome Measures for Psoriasis: The IDEOM Report from the GRAPPA 2016 Annual Meeting. <i>Journal of Rheumatology</i> , 2017 , 44, 701-702 | 4.1 | 5 |

| | | | |
|----|---|-----|-----|
| 81 | From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2017 , 76, 290-298 | 4.5 | 90 |
| 80 | Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. <i>Lancet, The</i> , 2017 , 389, 2317-2327 | 4.0 | 246 |
| 79 | Anti IL-17 flared psoriasis in a patient on secukinumab. <i>Dermatologic Therapy</i> , 2017 , 30, e12505 | 2.2 | 6 |
| 78 | Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib. <i>Journal of the American Academy of Dermatology</i> , 2017 , 76, 1054-1060.e1 | 4.5 | 98 |
| 77 | Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study. <i>Rheumatology</i> , 2017 , 56, 1993-2003 | 3.9 | 92 |
| 76 | Greater Efficacy with Secukinumab Treatment is Associated with Greater Psoriasis Symptom Relief: Results from Secukinumab Clinical Trial Data. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2017 , 2, 73-80 | 1.1 | 1 |
| 75 | Patient-Reported Outcomes Measures in Psoriasis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2017 , 2, 41-46 | 1.1 | 1 |
| 74 | Patient Research Partners: Lessons Learned from OMERACT Applied to Dermatology. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2017 , 2, 92-96 | 1.1 | |
| 73 | Comment on "Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis". <i>Journal of Investigative Dermatology</i> , 2017 , 137, 2642-2644 | 4.3 | 2 |
| 72 | Assessing clinical response and defining minimal disease activity in plaque psoriasis with the Physician Global Assessment and body surface area (PGA/BSA) composite tool: An analysis of apremilast phase 3 ESTEEM data. <i>Journal of the American Academy of Dermatology</i> , 2017 , 77, 1178-1180 | 4.5 | 13 |
| 71 | Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial. <i>Journal of the American Academy of Dermatology</i> , 2017 , 76, 70-80 | 4.5 | 87 |
| 70 | High-dose ustekinumab for the treatment of severe, recalcitrant pyoderma gangrenosum. <i>Dermatologic Therapy</i> , 2016 , 29, 482-483 | 2.2 | 28 |
| 69 | Psoriasis. <i>Nature Reviews Disease Primers</i> , 2016 , 2, 16082 | 5.1 | 327 |
| 68 | Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2). <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1984-1988 | 2.4 | 101 |
| 67 | Adaptive Clinical Trial Design: An Overview and Potential Applications in Dermatology. <i>Journal of Investigative Dermatology</i> , 2016 , 136, 1325-1329 | 4.3 | 4 |
| 66 | Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2016 , 68, 1060-71 | 9.5 | 485 |
| 65 | Translating psoriasis guidelines into practice: Important gaps revealed. <i>Journal of the American Academy of Dermatology</i> , 2016 , 74, 544-51 | 4.5 | 3 |
| 64 | Secukinumab for treating plaque psoriasis. <i>Expert Opinion on Biological Therapy</i> , 2016 , 16, 119-28 | 5.4 | 16 |

| | | | |
|----|---|------|-----|
| 63 | The Challenge of Managing Psoriasis: Unmet Medical Needs and Stakeholder Perspectives. <i>American Health and Drug Benefits</i> , 2016 , 9, 504-513 | 1.7 | 49 |
| 62 | Article Commentary: CorronaQ Application in Psoriatic Disease. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2016 , 1, 92-95 | 1.1 | |
| 61 | Secukinumab Provides Clearer Skin and Better Control on Patient-Reported Psoriasis Symptoms of Itching, Pain, and Scaling than Placebo and Etanercept. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2016 , 1, 167-174 | 1.1 | 0 |
| 60 | Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trials. <i>International Journal of Dermatology</i> , 2016 , 55, 401-7 | 1.7 | 27 |
| 59 | Psoriasis Trends and Practice Gaps. <i>Dermatologic Clinics</i> , 2016 , 34, 235-42 | 4.2 | 6 |
| 58 | Methotrexate improves pro- and anti-atherogenic genomic expression in psoriatic skin. <i>Journal of Dermatological Science</i> , 2016 , 82, 207-9 | 4.3 | 3 |
| 57 | International Dermatology Outcome Measures Initiative as Applied to Psoriatic Disease Outcomes: An Update. <i>Journal of Rheumatology</i> , 2016 , 43, 959-60 | 4.1 | 7 |
| 56 | Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials. <i>Journal of the American Academy of Dermatology</i> , 2016 , 75, 1156-1161 | 4.5 | 28 |
| 55 | Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. <i>New England Journal of Medicine</i> , 2016 , 375, 422-34 | 59.2 | 324 |
| 54 | Ustekinumab Treatment and Improvement of Physical Function and Health-Related Quality of Life in Patients With Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2016 , 68, 1812-1822 | 4.7 | 19 |
| 53 | Insights on methotrexate in psoriatic disease. <i>Clinical Immunology</i> , 2016 , 172, 61-64 | 9 | 8 |
| 52 | Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2015 , 386, 1137-46 | 4.0 | 566 |
| 51 | CCL20 and IL22 Messenger RNA Expression After Adalimumab vs Methotrexate Treatment of Psoriasis: A Randomized Clinical Trial. <i>JAMA Dermatology</i> , 2015 , 151, 837-46 | 5.1 | 30 |
| 50 | Psoriatic arthritis for the dermatologist. <i>Dermatologic Clinics</i> , 2015 , 33, 127-48 | 4.2 | 8 |
| 49 | Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase III Trial. <i>Arthritis Care and Research</i> , 2015 , 67, 1739-49 | 4.7 | 71 |
| 48 | The Comparative Efficacy of Traditional Systemic, Biologic, and Combination Therapies in the Treatment of Psoriasis: An Expansion Study. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2015 , 1, 18-26 | 1.1 | |
| 47 | Effect of Pregnancy on Psoriasis and Psoriatic Arthritis. <i>Psoriasis Forum</i> , 2015 , 21a, 12-27 | | |
| 46 | Analysis of Gender Differences in the Efficacy of Psoriasis Treatment Modalities Resulting in Clearance. <i>Psoriasis Forum</i> , 2015 , 21a, 28-34 | | |

| | | | |
|----|--|-----|-----|
| 45 | First-In-Human, Phase 1, Randomized, Dose-Escalation Trial with Recombinant Anti-IL-20 Monoclonal Antibody in Patients with Psoriasis. <i>PLoS ONE</i> , 2015 , 10, e0134703 | 3.7 | 13 |
| 44 | Assessment of the Use of Adrenocorticotrophic Hormone in Psoriatic Arthritis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2015 , 1, 52-58 | 1.1 | |
| 43 | Treatment of coexistent psoriasis and lupus erythematosus. <i>Journal of the American Academy of Dermatology</i> , 2015 , 72, 253-60 | 4.5 | 29 |
| 42 | The International Dermatology Outcome Measures Group: formation of patient-centered outcome measures in dermatology. <i>Journal of the American Academy of Dermatology</i> , 2015 , 72, 345-8 | 4.5 | 31 |
| 41 | Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). <i>Journal of Drugs in Dermatology</i> , 2015 , 14, 706-14 | 2.2 | 187 |
| 40 | Secukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 Trials. <i>Journal of Drugs in Dermatology</i> , 2015 , 14, 821-33 | 2.2 | 37 |
| 39 | Specific targeting of interleukin-23p19 as effective treatment for psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2014 , 70, 555-61 | 4.5 | 54 |
| 38 | Research gaps in psoriasis: opportunities for future studies. <i>Journal of the American Academy of Dermatology</i> , 2014 , 70, 146-67 | 4.5 | 85 |
| 37 | Safety and efficacy of therapies for skin symptoms of psoriasis in patients with psoriatic arthritis: a systematic review. <i>Journal of Rheumatology</i> , 2014 , 41, 2301-5 | 4.1 | 11 |
| 36 | ICD-10 for the Dermatologist and Psoriasis Care Provider. <i>Psoriasis Forum</i> , 2014 , 20a, 104-107 | | |
| 35 | The International Dermatology Outcome Measures initiative as applied to psoriatic disease outcomes: a report from the GRAPPA 2013 meeting. <i>Journal of Rheumatology</i> , 2014 , 41, 1227-9 | 4.1 | 16 |
| 34 | Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies. <i>Journal of Drugs in Dermatology</i> , 2014 , 13, 1441-8 | 2.2 | 52 |
| 33 | Outcome Measures in Psoriasis and Psoriatic Arthritis. <i>Current Dermatology Reports</i> , 2013 , 2, 159-163 | 1.5 | 2 |
| 32 | Psoriasis outcome measures: a report from the GRAPPA 2012 annual meeting. <i>Journal of Rheumatology</i> , 2013 , 40, 1428-33 | 4.1 | 18 |
| 31 | Ustekinumab in the treatment of psoriatic arthritis: latest findings and clinical potential. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2013 , 5, 277-85 | 3.8 | 30 |
| 30 | A Review of Home Phototherapy and Available Home and Handheld Phototherapy Units. <i>Psoriasis Forum</i> , 2013 , 19a, 71-75 | | 0 |
| 29 | Merits of Mycophenolate Mofetil for Psoriasis: Is It Effective?. <i>Psoriasis Forum</i> , 2013 , 19a, 176-181 | | |
| 28 | Psoriasis: Ustekinumab and Other Biologics in the Pipeline. <i>Current Dermatology Reports</i> , 2012 , 1, 108-114 | 4.5 | 1 |

| | | | |
|----|---|-----|-----|
| 27 | Safety Updates on Tumor Necrosis Factor Blockers. <i>Psoriasis Forum</i> , 2012 , 18a, 98-109 | | |
| 26 | Impact of Accountable Care Organizations on Psoriasis Care. <i>Psoriasis Forum</i> , 2012 , 18a, 221-224 | | |
| 25 | The Therapeutic Applications of Janus Kinase Inhibition in Psoriasis. <i>Psoriasis Forum</i> , 2012 , 18a, 118-125 | | |
| 24 | Psoriasis in the elderly: from the Medical Board of the National Psoriasis Foundation. <i>Journal of the American Academy of Dermatology</i> , 2011 , 65, 537-545 | 4.5 | 53 |
| 23 | C-Reactive Protein and Cardiovascular Disease in Psoriasis. <i>Psoriasis Forum</i> , 2011 , 17a, 24-32 | | |
| 22 | Psoriatic Eye Manifestations. <i>Psoriasis Forum</i> , 2011 , 17a, 169-179 | | 7 |
| 21 | Management of psoriatic arthritis from the view of the dermatologist. <i>Nature Reviews Rheumatology</i> , 2011 , 7, 588-98 | 8.1 | 41 |
| 20 | Nail Psoriasis: A Review of Treatment. <i>Psoriasis Forum</i> , 2010 , 16a, 35-43 | | |
| 19 | Psoriasiform Eruption following the Treatment of Cutaneous Sarcoidosis with Infliximab. <i>Psoriasis Forum</i> , 2010 , 16a, 64-66 | | |
| 18 | Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. <i>Journal of the American Academy of Dermatology</i> , 2010 , 62, 114-135 | 4.5 | 267 |
| 17 | Validation and response to treatment of a pruritus self-assessment tool in patients with moderate to severe psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2010 , 63, 580-6 | 4.5 | 18 |
| 16 | Comorbidities in patients with psoriasis. <i>American Journal of Medicine</i> , 2009 , 122, 1150.e1-9 | 2.4 | 125 |
| 15 | Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. <i>Lancet, The</i> , 2009 , 373, 633-40 | 4.0 | 476 |
| 14 | Current biologic treatments for psoriasis. <i>Dermatology Nursing / Dermatology Nurses Association</i> , 2009 , 21, 259-66, 272; quiz 267 | | |
| 13 | Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. <i>Journal of the American Academy of Dermatology</i> , 2008 , 58, 851-64 | 4.5 | 349 |
| 12 | Psoriasis comorbidities. <i>Journal of Dermatological Treatment</i> , 2008 , 19, 5-21 | 2.8 | 183 |
| 11 | Focus on psoriatic arthritis and comorbidities. <i>Expert Review of Dermatology</i> , 2008 , 3, S35-S36 | | 2 |
| 10 | Psoriasis and the metabolic syndrome. <i>Journal of Drugs in Dermatology</i> , 2008 , 7, 563-72 | 2.2 | 47 |

| | | | |
|---|--|-----|-----|
| 9 | Consistency of Infliximab Response across Subgroups of Patients with Psoriasis: Integrated Results from Randomized Clinical Trials. <i>Psoriasis Forum</i> , 2007 , 13a, 21-27 | | 10 |
| 8 | Safety and Tolerability of 60 Weeks Extended Efalizumab Therapy in Patients with Chronic Moderate to Severe Plaque Psoriasis. <i>Psoriasis Forum</i> , 2007 , 13a, 28-33 | | |
| 7 | Tumor necrosis factor blockade: mechanism of action. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2007 , 12, 1-4 | 1.1 | 28 |
| 6 | A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis. <i>Current Medical Research and Opinion</i> , 2007 , 23, 1081-92 | 2.5 | 85 |
| 5 | Consensus on a core set of domains for psoriatic arthritis. <i>Journal of Rheumatology</i> , 2007 , 34, 1167-70 | 4.1 | 144 |
| 4 | Clinical characteristics of psoriatic arthritis and psoriasis in dermatologists' offices. <i>Journal of Dermatological Treatment</i> , 2006 , 17, 279-87 | 2.8 | 57 |
| 3 | Use of etanercept for psoriatic arthritis in the dermatology clinic: the Experience Diagnosing, Understanding Care, and Treatment with Etanercept (EDUCATE) study. <i>Journal of Dermatological Treatment</i> , 2006 , 17, 343-52 | 2.8 | 38 |
| 2 | Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. <i>Journal of the American Academy of Dermatology</i> , 2004 , 51, 534-42 | 4.5 | 464 |
| 1 | Etanercept as monotherapy in patients with psoriasis. <i>New England Journal of Medicine</i> , 2003 , 349, 2014-22 | 5.2 | 978 |